MAGEA6 (MAGE Family Member A6)

Serum MAGEA3-IgG levels are significantly elevated in LUAD patients, and this autoantibody is anticipated to serve as a critical biomarker for early diagnosis, treatment monitoring, and prognostic evaluation in LUAD.

Further analysis confirmed that BCL11B and PAEP expression levels were significantly associated with immune cell infiltration and immune regulatory activity. MAGEA3/6 expression defines immune subtypes in GC and highlights potential targets for immunotherapy.

Collectively, Our Findings Provide a Comprehensive Overview of Clinically Relevant Molecular Subtypes of CRC-SCs, Representing the Current Landscape of CRC Molecular Expression Subtypes. They Also Enable Rapid, Low-Cost Outcome Prediction and Suggest Potential Targets for Therapeutics Development.

These findings suggest that MAGEA6 enhances CRC invasiveness and PNI by stabilizing YY1, which upregulates CXCL1 secretion and promotes SC recruitment. This interaction underscores the critical role of MAGEA6 in PNI and highlights a potential therapeutic target in CRC.

Furthermore, we also observed that AMPK is required for SLC7A11 to regulate ferroptosis, and supported the crux roles of MAGEA6/AMPK/SLC7A11-mediated ferroptosis on modulating DOX sensitivity in TNBC cells. These findings indicated that targeting MAGEA6 can enhance the chemo-sensitivity in TNBC via activation of autophagy and ferroptosis; its mechanism involves AMPKα1-dependent autophagy and AMPKα1/SLC7A11-induced ferroptosis.

This study successfully developed a six-gene necroptosis-related signature to predict prognoses in HCC patients. It further explored the roles of necroptosis in hepatoma cells and the tumor microenvironment.

Our findings suggested that a four-mRNA panel may be promising in the non-invasive diagnosis of NMIBC, which deserves further investigation.

Deconvolution analysis with single-cell RNAseq data confirmed the presence of specific cell clusters in FFPE samples. We propose these 530 DEGs as a molecular fingerprint of osteosarcoma.

We also found knockdown UCK2 changed expressions of immune genes in HCC cell lines. The novel stemness-related model could predict the prognosis of patients and aid in creating personalized immuno- and targeted therapy for patients in HCC.

Our study first identify vulnerability to ferroptosis by regulating MAGEA6-AMPK-SLC7A11-GPX4 signaling pathway. Combined treatment with HMAs and FINs provides a potential therapeutic choice for AML patients, especially for R/R-AML.

The positive rate of the model combined with cytokeratin 19 fragment to diagnose ESCC reached 78.0%. The study identified anti-MAGEA autoantibodies with potential diagnostic value for ESCC, which may provide new promising for the detection of the disease.

Moreover, the TME subtypes were associated with patients' overall survival and response to daratumumab...These findings highlight the importance of TME analysis in predicting treatment response and MM patients' outcome in the context of immune-based therapies. Our integrative multi-omics analysis revealed comprehensive MM heterogeneity and distinct immune subtypes that could be of therapeutic interest for personalized therapeutic approaches.